BioTuesdays

Author - Leonard Zehr

Dipexium Pharmaceuticals
Developments

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients...

February 4, 2016
Bionomics
Markets

Roth starts Bionomics at buy

Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday.“We believe a significant disconnect exists on the...

February 3, 2016
Carbylan Therapeutics
Markets

Leerink downgrades Carbylan to market perform

Leerink Partners has downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” from “outperform” and slashed its price target to $1.83 from $15 after the company reported a disappointing Phase 3 readout for...

February 2, 2016
Feature

In conversation with Amir Ronen

By Len Zehr As a founding member of closely-held Sensible Medical Innovations, Amir Ronen also has held the title of CEO since the company’s inception in late 2007. Mr. Ronen has over 15 years of experience in senior...

February 2, 2016
EyeGate Pharmaceuticals
Markets

Rodman starts EyeGate Pharma at buy

Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday. “In our view, the company’s EGP-437...

February 1, 2016
Volition
Markets

Rodman starts VolitionRx at buy

Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday. “In our view, the company’s blood-based NuQ screening...

February 1, 2016
BioBlast Pharma
Markets

Rodman starts BioBlast Pharma at buy

Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday. BioBlast is focused on platform-based solutions...

January 28, 2016